Abstract
This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Singleton Hospital, Swansea Bay University Health Board, Department of Diabetes and Endocrinology, Swansea, UK (GRID:grid.415947.a) (ISNI:0000 0004 0649 0274)
2 Singleton Hospital, Swansea Bay University Health Board, Department of Diabetes and Endocrinology, Swansea, UK (GRID:grid.415947.a) (ISNI:0000 0004 0649 0274); Swansea University Medical School, Diabetes Research Group, Swansea, UK (GRID:grid.4827.9) (ISNI:0000 0001 0658 8800)
3 Swansea University Medical School, Diabetes Research Group, Swansea, UK (GRID:grid.4827.9) (ISNI:0000 0001 0658 8800); Swansea Bay University Health Board, Department of Diabetes and Endocrinology, Neath Port Talbot Hospital, Swansea, UK (GRID:grid.461297.f) (ISNI:0000 0004 0648 9329)